Sweden
Biopharma Executive · Scientist · Founder
Turning complex science into enduring value.
Dr. Mitra Mosharraf is a biopharma executive and pharmaceutical scientist advancing biologics, drug product, and nanomedicine through rigorous development, strategic partnerships, and entrepreneurial leadership.
25+Years in biopharma
300+Client programs
20+Peer-reviewed papers
MPharm & PhD, Uppsala University, Sweden
Executive MBA, MIT Sloan, USA
01 Perspective
“The strongest development strategies respect both the science in front of us and the decisions still ahead.”
Mitra operates at the point where scientific judgment, development strategy, and business opportunity meet. Her career spans global pharmaceutical companies, emerging biotechnology ventures, and a specialized US development organization serving innovators across the industry.
Born in Iran, educated in Sweden and the United States, and based in the San Francisco Bay Area, she brings an international perspective to leadership. Her work is grounded in evidence, shaped by entrepreneurship, and focused on helping promising technologies become viable products.
Education & Credentials
Scientific rigor.
Executive range.
United States
MIT Sloan School of Management
Executive MBA · Certificate in Business AnalyticsSpecialized Leadership
AI, Business & Executive Leadership
MIT Sloan AI in Pharma & Biotech · Cornell Executive LeadershipProfessional
Licensed Pharmacist
Swedish National Board of Health and Welfare02 Expertise
Depth in science.
Range in leadership.
Biologics & Drug Product
Formulation, delivery, analytical strategy, and CMC leadership across proteins, antibodies, peptides, vaccines, and complex injectables.
Nanomedicine Innovation
Deep experience with liposomes, lipid nanoparticles, adjuvants, and the practical path from platform science to developable products.
Partnerships & Growth
Scientific business development, diligence, alliance building, and high-stakes decisions at the intersection of R&D and enterprise value.
03 Leadership
Building platforms,
capabilities, and communities.
HTD Biosystems
Executive Vice President & Chief Scientific Officer
Leading scientific strategy and drug-product development for biotechnology and pharmaceutical innovators, while connecting technical excellence with client value and growth.
Engimata
Technical Co-Founder & Chief Executive Officer
Advancing thermostable liposomal adjuvant and vaccine technologies, translating invention into protected intellectual property and commercial opportunity.
Tri Valley Biosolutions
Co-Founder & Managing Partner
Building a Bay Area life-science platform through R&D infrastructure, facility development, and strategic business stewardship.
American Association of Pharmaceutical Scientists (AAPS)
Focus Group Lead, Formulation and Delivery of Biologics and Advanced Modalities
Leading scientific programming, publications, and cross-disciplinary exchange in biologics formulation, drug delivery, and advanced therapeutic modalities. Previously served as Chair of the AAPS Nanotechnology Community.
04 Impact
A career of translating possibility into progress.
05 Speaking
Advancing the scientific conversation.
Webinar · Scientific Leadership
Current State of Nanomedicine Drug Products: An Industry Perspective
AAPS Science360 · January 2026MIT event page ↗Webinar details ↗Hot Topic · Speaker
Strategies for Manufacturing and Analysis of Lipid-Based Nanomedicines and Vaccines
AAPS PharmSci360 · 2025Presentation details ↗Hot Topic · Moderator & Speaker
Limitations of AI/ML, Regulatory Requirements and Future Perspective
AAPS PharmSci360 · 2025Presentation details ↗Session overview ↗LinkedIn recap ↗Rapid-Fire Presentation
Design of Experiments to Accelerate Formulation Development of Complex Modalities
AAPS NBC · Boston, MA · May 2025Presenter profile ↗Scientific Posters · Presenter
Liposomal Vaccine Characterization and Liposome Aggregation
AAPS PharmSci360 · 2024Presenter profile ↗Webinar · Moderator
Design of Lipid Nanoparticles to Enable Gene Therapies
AAPS Science360 · September 2025 · With Pieter CullisWebinar details ↗Webinar · Moderator
Liposomes—from the Laboratory to the Clinic
AAPS Science360 · May 2025 · With Francis SzokaWebinar details ↗Scientific Moderation
Scientific Conversation with Raj Suryanarayanan
AAPS Scientific Exchange · 2025Conference Presentation
Prediction and Prevention of Protein Aggregation in Multi-Dose Products
9th World Drug Delivery Summit · 2016Abstract ↗Keynote
Keynote on Pharmaceutical Market Trends
Pharma Market Research Conference · San Francisco · June 2023LinkedIn recap ↗06 Selected work
Ideas for the next generation of medicines.
Cover article · 2019
Coformulation Development of Biologics in Combination Drugs
AAPS Newsmagazine ↗Publication · 2024
The Role of Artificial Intelligence and Machine Learning in Accelerating the Discovery and Development of Nanomedicine
Pharmaceutical Research ↗Publication · 2026
Lipid Nanoparticle Development in Practice: Challenges and Collective Insights
Pharmaceutical Research ↗Book chapter · 2026
Manufacturing Nanomedicines and Nanovaccines: Challenges and Issues
Elsevier Academic Press ↗07 Media & interviews
Ideas shared beyond the podium.
Podcast · 2025–2026
From Discovery to Delivery: AI's Impact on Nanomedicine
Data in Biotech by CorrDyn
Interview · 2025
Manufacturing Lipid-Based Nanomedicines and Vaccines
European Pharmaceutical Manufacturer
Interview · 2025
AAPS Member Spotlight: Mitra Mosharraf
AAPS Newsmagazine
Industry conversation · 2024
CDMO Offers FlowCam Analytical Services and Formulation Development
Yokogawa Fluid Imaging
08 Advisory
Selective expertise for consequential decisions.
Mitra accepts select consulting and advisory engagements where scientific depth, development experience, and commercial judgment can materially improve an outcome.
Biologics CMC & Drug Product Strategy
Phase-appropriate formulation, analytical, process, stability, and development strategy for biologics and complex injectable products.
Scientific Market Intelligence
Market landscaping, competitive assessment, voice-of-customer research, and opportunity analysis grounded in scientific and industry context.
Diligence, Partnerships & Externalization
Technical diligence, CDMO and CRO selection, development-risk assessment, partnership strategy, and scientific-commercial decision support.
Board · Executive · Advisory · Speaking
Let's shape what comes next.
Mitra welcomes conversations about executive leadership, scientific strategy, board and advisory service, selective consulting, strategic partnerships, and the future of biologics and advanced drug delivery.
mitra@mitramosharraf.com